Will preemption rescue Medtronic from InFuse lawsuits?

October 24, 2013 by Brad Perriello

The preemption doctrine could save Medtronic from the raft of lawsuits it's facing over alleged off-label promotion of its InFuse bone putty.

Will preemption rescue Medtronic from InFuse lawsuits?

Medtronic (NYSE:MDT) could avoid a major headache if the courts continue to allow the doctrine of preemption in product liability lawsuits filed over its InFuse bone-growth protein, according to Fish & Richardson principal José Sierra.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Comments

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp